Antiviral efficacy upon administration of a HepDirect prodrug of 2′-C-methylcytidine to hepatitis C virus-infected chimpanzees

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3854-3860

  Carroll, Steven S ^a   Koeplinger, Kenneth ^a   Vavrek, Marissa ^a   Zhang, Nanyan Rena ^a   Handt, Laurence ^a   MacCoss, Malcolm ^a   Olsen, David B ^a   Reddy, K Raja ^b   Sun, Zhili ^b   Van Poelje, Paul D ^b   Fujitaki, James M ^b   Boyer, Serge H ^b   Linemeyer, David L ^b   Hecker, Scott J ^b,c   Erion, Mark D ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Metabasis Therapeutics Inc   (United States)

^c Mpex Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,5 DIFLUOROPHENYL) 1,3 PROPANDIOL; 2' METHYLCYTIDINE; ANTIVIRUS AGENT; COMPOUND 1; COMPOUND 5A; COMPOUND 5B; COMPOUND 5C; COMPOUND 5D; COMPOUND 5E; COMPOUND 5F; COMPOUND 5G; COMPOUND 5H; COMPOUND 6; COMPOUND 7; NUCLEOSIDE ANALOG; NUCLEOSIDE TRIPHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CELL ACTIVATION; CHIMPANZEE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; CYTIDINE; CYTIDINE MONOPHOSPHATE; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; MACACA MULATTA; MALE; PAN TROGLODYTES; PRODRUGS; PYRIMIDINE NUCLEOSIDES; RATS; RATS, SPRAGUE-DAWLEY; VIRAL LOAD;

EID: 79960300296     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01152-10     Document Type: Article

References (28)

1. Afdhal, N., et al. 2007. Valopicitabine (NM 283), alone or with peg-interferon, compared to peg-interferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: one year results. J. Hepatol. 46(Suppl. 1):S5.
2. Afdhal, N., et al. 2006. Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (pegIFN/RBV) re-treatment in hepatitis C patients with prior non-response to pegIFN/RBV: week 24 results. J. Hepatol. 44(Suppl. 2):S19.
3. Berry, M. N., and D. S. Friend. 1969. High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J. Cell Biol. 43:506-520.
4. Carroll, S., et al. 2009. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother. 53:926-934.
5. Erion, M. D., D. A. Bullough, C.-C. Lin, and Z. Hong. 2006. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Curr. Opin. Invest. Drugs 7:109-117.
6. Erion, M. D., K. R. Reddy, S. H. Boyer, M. C. Matelich, J. Gomez-Galeno, R. H. Lemus, B. G. Ugarkar, T. J. Colby, J. Schanzer, and P. D. Van Poelje. 2004. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 126:5154-5163.
7. Erion, M. D., et al. 2005. Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312:554-560.
8. Fung, E. N., Z. Cai, T. C. Burnette, and A. K. Sinhababu. 2003. Simultaneous determination of Ziagen and its phosphorylated metabolites by ion-pairing high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 754:285-295.
9. Groen, A. K., H. J. Sips, R. C. Vervoorn, and J. M. Tager. 1982. Intracellular compartmentation and control of alanine metabolism in rat liver parenchymal cells. Eur. J. Biochem. 122:87-93.
10. Hecker, S. J., et al. 2007. Liver-targeted prodrugs of 2′-methyladenosine for therapy of hepatitis C virus infection. J. Med. Chem. 50:3891-3896.
11. Kronenberger, B., and S. Zeuzem. 2009. Current and future treatment options for HCV. Ann. Hepatol. 8:103-112.
12. Lam, A. M., et al. 2010. PSI-7851, a pronucleotide of β-D-2′deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob. Agents Chemother. 54:3189-3196.
13. Lauer, G. M., and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52.
14. Lawitz, E., et al. 2007. Clearance of HCV RNA with valopicitabine (NM 283) plus peg-interferon in treatment-naive patients with HCV-1 infection: results at 24 and 48 weeks. J. Hepatol. 46(Suppl. 1):S9.
15. Le Pogam, S., et al. 2006. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349-359.
16. McCown, M. F., et al. 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52:1604-1612.
17. McGuigan, C., et al. 2009. The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4′-azidocytidine (R1479). Bioorg. Med. Chem. Lett. 19:4250-4254.
18. McGuigan, C., et al. 2010. Design, synthesis and evaluation of a novel double pro-drug: INX-008189. A new clinical candidate for hepatitis C virus. Bioorg. Med. Chem. Lett. 20:4850-4854.
19. McGuigan, C., P. Perrone, K. Madel, and J. Neyts. 2009. The phosphoramidate ProTide approach greatly enhances the activity of β-2′-C-methylguanosine against hepatitis C virus. Bioorg. Med. Chem. Lett. 19:4316-4320.
20. O'Brien, C., et al. 2005. Randomized trial of valopicitabine (NM 283), alone or with peg-interferon, vs retreatment with peg-interferon plus ribavirin (peg-IFN/RBV) in hepatitis C patients with previous non-response to Peg-IFn/RBV: first interim results. Hepatology 42(Suppl.):234A.
21. Pierra, C., et al. 2006. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C- methylcytidine. J. Med. Chem. 49:6614-6620.
22. Pockros, P. J., et al. 2007. Robust synergistic antiviral effect of R1626 in combination with peginterferon alfa-2a (40kD), with or without ribavirin: interim analysis results of phase 2a study. Hepatology. 46(Suppl.):311A.
23. Reddy, K. R., S. H. Boyer, and M. D. Erion. 2005. Stereoselective synthesis of nucleoside monophosphate HepDirect prodrugs. Tetrahedron Lett. 46: 4321-4324.
24. Reddy, K. R. May 2003. Phosphonic acid based prodrugs of PMEA and its analogues. U.S. patent 7,214,668.
25. Rodriguez-Torres, M., et al. 2008. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with PeG-IFN and ribavirin: subanalysis by race/ethnicity, weight and HCV genotype. Hepatology 48(Suppl.):1160A.
26. Standring, D. N., et al. 2009. Antiviral activity of the liver-targeted nucleotide HCV polymerase inhibitor IDX184 correlates with trough serum levels of the nucleoside metabolite in HCV-infected chimpanzees. J. Hepatol. 42(Suppl.):S37.
27. Standring, D. 2003. NM283 has potent antiviral activity against chronic infection with hepatitis C virus, genotype 1, in the chimpanzee. European Association for the Study of the Liver, Geneva, Switzerland.
28. Zeuzem, S. 2008. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat. Clin. Pract. Gastroenterol. Hepatol. 5:610-622.